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HIGHLIGHTS
 ICHOM seeks to help standardize and align outcome measurement efforts globally.
 Standardization and alignment of this sort does not exist for heart failure.
 The heart failure working group developed a standard set of 17 outcomes to be measured.
 ICHOM hopes this standardization effort will increase quality and value in heart failure care.ABSTRACTISSWhereas multiple national, international, and trial registries for heart failure have been created, international standards
for clinical assessment and outcome measurement do not currently exist. The working group’s objective was to facilitate
international comparison in heart failure care, using standardized parameters and meaningful patient-centered outcomes
for research and quality of care assessments. The International Consortium for Health Outcomes Measurement recruited
an international working group of clinical heart failure experts, researchers, and patient representatives to define a
standard set of outcomes and risk-adjustment variables. This was designed to document, compare, and ultimately
improve patient care outcomes in the heart failure population, with a focus on global feasibility and relevance. The
working group employed a Delphi process, patient focus groups, online patient surveys, and multiple systematic publi-
cations searches. The process occurred over 10 months, employing 7 international teleconferences. A 17-item set has
been established, addressing selected functional, psychosocial, burden of care, and survival outcome domains. These
measures were designed to include all patients with heart failure, whether entered at first presentation or subsequent
decompensation, excluding cardiogenic shock. Sources include clinician report, administrative data, and validated
patient-reported outcome measurement tools: the Kansas City Cardiomyopathy Questionnaire; the Patient Health
Questionnaire-2; and the Patient-Reported Outcomes Measurement Information System. Recommended data included
those to support risk adjustment and benchmarking across providers and regions. The International Consortium for
Health Outcomes Measurement developed a dataset designed to capture, compare, and improve care for
heart failure, with feasibility and relevance for patients and clinicians worldwide. (J Am Coll Cardiol HF 2020;8:212–22)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2019.09.007
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AND ACRONYM S
ICHOM = International
Consortium for Health
Outcomes Measurement
KCCQ = Kansas City
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MLHFQ = Minnesota Living
with Heart Failure
Questionnaire
PROM = patient-reported
outcome measureC ardiovascular diseases are responsible for asignificant burden on patients and healthcare systems worldwide (1,2). Although
prevalence estimates in the developing world are
largely lacking, heart failure affects up to 2% of the
adult population in the developed world, with cur-
rent estimates over the period of 2002 to 2014 sug-
gesting an absolute increase in heart failure
incidence and prevalence (3–5). Estimates of the
annual costs of heart failure treatment in the Unites
States alone exceed $30 billion, over one-half of
which is due to hospitalization (6). It is therefore
fundamental to be able to effectively monitor and
manage this disease process.
Major guidelines exist for heart failure manage-
ment, recommending therapies that affect the course
of the disease. However, these guidelines most
commonly focus on mortality, hospitalization, or
surrogate measures such as change in ejection frac-
tion or ventricular remodeling (6–8). Though
reducing symptoms and increasing functional capac-
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achieve these outcomes. Additionally, the
many international studies and registries that
exist exhibit marked heterogeneity in terms
of what is measured and the definitions
thereof and tend to neglect patient-reported
outcomes (9). This has the effect of limiting
international comparison and our under-
standing of the burden of heart failure on
quality of life and physical function.
The International Consortium for Health
Outcomes Measurement (ICHOM) seeks to
promote comprehensive standardized outcome mea-
surement and align outcome measurement efforts
globally. To this end, a heart failure working group
was formed. The goal of the working group was to
define a standard pragmatic patient-centered
outcome set to improve patient care and permit
comparison across regions and health care systems.
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goal was to include sufficient detail to be meaningful,linic, Cleveland, Ohio; bInternational Consortium for
of Cardiology, University of Adelaide, Adelaide,
zil; eHospital Universitario de A Coruna, A Coruna
oruna, Spain; fHeart Failure Unit, Attikon University
ington Hospital, London, United Kingdom; hJulius
echt, Utrecht, the Netherlands; iDepartment of Car-
ales, United Kingdom; jLeducq Corporation, Boston,
ited Kingdom; lBritish Heart Foundation, London,
apore and Duke-National University of Singapore,
Colorado Anschutz Medical Campus, Aurora, Colo-
Heart Association, Dallas, Texas; qDepartment of
Service England–London Diabetes Clinical Network,
itutet, Stockholm, Sweden; tSchool of Public Health
lty of Medicine, Imperial College London, London,
ersity, Nashville, Tennessee; and the wCardiology
atient representative. Funding for this project was
oard, British Heart Foundation, American Heart As-
f the European Society of Cardiology. Dr. Arora is
ts from Servier Laboratories, AstraZeneca, and Bio-
ees, and institutional research support fromNovartis;
s Rares; travel grants from Vifor Pharma and Servier;
, and Astellas. Dr. Filippatos has received research
man has received an institutional research grant from
uropean Commission: Research and Innovation. Dr.
rt Association and European Society of Cardiology
linician Scientist Award from the National Medical
Scientific, Bayer, Roche Diagnostics, AstraZeneca,
sory Board, Steering Committee, or Executive Com-
ic, Vifor Pharma, Novartis, Amgen, Merck, Janssen
Nordisk, Abbott Diagnostics, Corvia, Stealth Bio-
lobal LLC, and Radcliffe Group Ltd. Dr. Masoudi is the
ovascular Data Registry programs. Dr. McIntyre has
rtis Pharma, Vifor Pharma, and Servier; and research
Institute for Health and Care Excellence 2010 Chronic
. JudeMedical andNovartis; and consulting fees from
ips relevant to the contents of this paper to disclose.
er 16, 2019, accepted September 16, 2019.
Burns et al. J A C C : H E A R T F A I L U R E V O L . 8 , N O . 3 , 2 0 2 0
Standardized Outcome Measurement in Heart Failure M A R C H 2 0 2 0 : 2 1 2 – 2 2
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collected data to ensure feasibility, considering also
cost and time required for set implementation.
METHODS
WORKING GROUP COMPOSITION AND PROCESS. An
international working group was formed from recog-
nized experts in heart failure, epidemiology, and
public health. Allied health professionals, patient
advocates, and patient representatives were also
included. The primary criterion for being invited to
join the working group was expertise in the condition
or, in the case of patient representatives, personal
experience with heart failure. Working group mem-
bers were identified through their published work,
through ICHOM’s professional network, or through
recommendations from experts in the field. The
working group lead was a heart failure cardiologist
(T.M.) with significant clinical, research, and guide-
line development experience. A project team was also
formed that included a project leader (J.A. then O.O.)
as well as a research fellow (D.B.) who managed the
process and teleconferences, communicated with the
working group, and provided the supporting research
efforts underlying each teleconference. Industry
representatives were deliberately excluded from the
process in line with ICHOM policy to avoid the
perception of bias toward any particular product or
service offered, though feedback was sought during
the final stages by means of an open review period.
Regulators and payers were not involved, as these
would necessarily vary across countries and health
care systems. As the focus of the set was its clinical
applicability, emphasis was placed on patients and
clinicians. Patient input was sought by means of
both a focus group and patient survey administered
by the project leader, with heart failure patients
representing the United Kingdom, United States, and
Brazil. English-speaking heart failure patients were
convened by videoconference and questioned as to
which outcomes were most meaningful, at what age
they were affected, and how daily life was affected
by their disease. Patients were surveyed via an on-
line questionnaire regarding agreement with the
outcome set capturing the outcomes that have mat-
tered most to them as patients. Comparison between
the patient-derived outcome set and the working
group–derived clinical outcomes helped inform
set development.
Our goal was to define a parsimonious 10- to 15-
item set of clinical outcomes that broadly encom-
passed mortality, morbidity, and patient-reported
health-related quality of life. The outcome set wasto be adequately comprehensive and sensitive to
detect a clinical change, prompting further investi-
gation or treatment escalation, while remaining
pragmatic in terms of measurement time and ease of
use, being feasible to implement at the primary care
level. The set’s use would not preclude collection and
reporting of additional data measures beyond those
specifically highlighted.
From May 25, 2015, to March 18, 2016, 7 interna-
tional teleconferences took place (Figure 1). Prior to
each teleconference, the project team summarized
key evidence sourced from clinical guidelines, rele-
vant scientific publications, and a large initial survey
of heart failure registry publications (Table 1). This
was circulated to the working group in advance of
each teleconference. A modified Delphi method was
utilized to achieve consensus on all major aspects of
set development.
The working group considered the following
criteria when selecting outcomes for inclusion: fre-
quency of occurrence for the outcome of interest;
the impact of a change in outcome on the patient;
outcome modification potential; the feasibility of
data collection at the primary care level; how
meaningful the outcome is as reported by survey or
focus group patients; and the cost to patients or
health care systems. For patient-reported outcome
measure (PROM) tools, additional criteria were
considered: domains of interest covered; clinical
interpretation of a change detected by the PROM
tool; comparison of the PROM tool to others in cur-
rent use; and the feasibility of the tool’s imple-
mentation at the primary care level. Time points for
data collection were defined for baseline patient
characteristics, PROM, and clinician-reported out-
comes. A set of risk adjustment variables was pro-
posed that included risk factors shown to affect the
clinical course of the heart failure patient, composed
of both demographic and health-related factors.
Evidence-based treatment variables affecting the
course of illness and quality of life were discussed
and included as well, as accurate placement of a
patient’s disease trajectory requires information
about therapies applied.
Following each teleconference, detailed minutes
were circulated along with a survey including each
specific discussion point. A two-thirds threshold was
required to adopt a decision, which would be formally
ratified at the subsequent teleconference. If two-
thirds was not reached, further discussion was un-
dertaken at the start of the following teleconference
with a second survey on these topics circulated, with
a majority decision adopted if two-thirds was still not
achieved.
FIGURE 1 Working Group Teleconference Flow Diagram
A flow diagram outlining the decision making process across the 7 teleconferences.
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215Members of the working group and project team
unanimously approved the final standard set and
accompanying data collection reference guide.
Funding for this project was provided in part by the
British Heart Foundation, American Heart Associa-
tion, European Society of Cardiology, and
Heart Failure Association of the European Society of
Cardiology. Several members of our working group
are actively involved these and other societies.
However, this project and its results have not been
formally endorsed by said societies.
As new evidence for heart failure management
emerges, this set will ultimately require revision to
remain in line with the evolving evidence base as well
as clinical guidelines. To this end, ICHOM will
implement a steering committee to oversee ongoing
revisions in line with new evidence.RESULTS
CONDITION SCOPE. The working group defined a
broad scope as it applies to heart failure. Consistent
with major guidelines, patients would be diagnosed
as having heart failure if they had clinically identified
heart failure signs and symptoms and objective evi-
dence of cardiac dysfunction (6–8). All patients with
the diagnosis of heart failure would be included,
whether presenting acutely or chronically, regardless
of etiology, and across the spectrum of ejection frac-
tion. Acute heart failure was classified as either an
acute first presentation or as an acute decompensa-
tion of chronic heart failure, whether or not it resul-
ted in a hospital admission.
Patients with a first presentation as cardiogenic
shock were excluded from the scope, as there is often
TABLE 1 Registries Informing Outcome, Risk-Adjustment Variable, and Complication Domains
Registry* Region Publication Date Range Index Population Current Population Presentation Clinical Setting Publications Reviewed
ADHERE America 2003–2014 27,645 >185,000 AHF I 31
ADHERE-I Asia-Pacific and Latin America 2011–2012 4,206 10,171 AHF I 3
AHEAD Czech Republic 2011–2015 4,153 5,057 AHF I 7
ALARM-HF Europe, Latin America, Australia 2010–2014 4,953 4,953 AHF I 5
ASIAN-HF North, East, and South Asia 2012–2016 6,480 6,480 CHF I/O 2
ATTEND Japan 2010–2015 1,110 4,842 AHF I 14
COHERE America 2000–2007 4,280 4,280 ChHF O 7
EFICA France 2006–2010 581 581 AHF I 4
EHFS II European Union 2006–2010 3,580 3,580 AHF I 3
ESC-HF-LT European Union 2010–2013 12,440 12,440 A/ChHF I/O 1
ESC-HF-P European Union 2010–2013 5,118 5,118 A/ChHF I/O 3
GWTG-HF America 2006–2015 59,965 65,032 AHF I 55
HIJC-HF Japan 2008 3,578 3,578 AHF I 1
IMPACT-HF America 2002–2005 363 567 AHF I 5
IMPROVE-HF America 2007–2014 15,381 15,177 ChHF O 13
IN-HF Italy 2012–2014 5,610 5,610 A/ChHF I/O 5
JCARE Japan 2006–2014 2,676 1,677 AHF I 18
KorHF Korea 2011–2015 3,200 3,200 AHF I 10
NICOR United Kingdom NR NR >200,000 AHF I 0
OPTIMIZE-HF America 2004–2014 48,612 48,612 AHF I 32
RO-AHFS Romania 2011–2015 3,224 3,224 AHF I 4
S-HFR Sweden 2010–2015 16,117 55,313 A/ChHF I/O 14
Thai-ADHERE Thailand 2010–2013 1,612 1,671 AHF I 2
THESUS-HF Sub-Saharan Africa 2012–2015 1,006 1,006 AHF I 5
*For detailed information and references by registry, please see the Online Table S1 and Online Appendix.
AHF ¼ acute heart failure; ChHF ¼ chronic heart failure; I ¼ inpatient; O ¼ outpatient; NR ¼ not reported.
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216a distinct upstream precipitating factor, which re-
quires urgent or emergent intervention. As such, the
patient does not fit in with the typical management
pattern for the general heart failure population.
However, patients surviving the initial event, with or
without aggressive medical or surgical intervention,
and continuing to be in heart failure, would be
included after stabilization. Similarly, patients with
coronary or valvular disease may fit the scope if pre-
senting with objective signs of ventricular dysfunc-
tion in the absence of immediately correctable causes
such as active ischemia. Patients with heart failure
who had undergone transplant or mechanical assis-
tance were considered outside the scope. These
populations present unique treatment challenges not
concordant with the majority of heart failure patients.
The scope did not include patients with isolated right
heart failure.
TREATMENT VARIABLES. Treatments included for
measurement and recording reflect the recommen-
dations of major evidence-based guidelines. These
therapies are known to affect mortality, hospitaliza-
tion, quality of life, or a combination of these in the
heart failure patient (6,8). Broadly, these can be
divided into pharmacotherapy, invasive therapies,
and rehabilitation. Pharmacotherapy includes allheart failure medications at baseline and any changes
made to the therapeutic regime over time. Invasive
therapies include devices such as pacemakers,
implantable cardioverter-defibrillators, and cardiac
resynchronization therapy, as well as cardiac surgery.
Cardiac rehabilitation program initiation was
included to complete the treatment options available
(Online Table S1). Treatment variables will be
captured through the patient’s medical record.
Ongoing treatment variable modifications will be
overseen by the ICHOM steering committee in line
with emerging evidence.
OUTCOME SET. To inform the development of the
outcome set and understand real world heart failure
outcome measurement efforts, the project team
compiled information sourced from 24 heart failure
registries. Ultimately, 241 discrete publications were
surveyed (Table 1). This phase documented outcome
domains, definitions, and ascertainment methods.
Registries predominantly focused on acute hospitali-
zations. Only a single registry included validated
PROM tools (10,11). Detailed registry and reference
information can be found in the Online Appendix
and Online Table S3.
The final outcome set includes 17 outcomes,
reflecting 4 domains: functional; psychosocial;
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217burden of care; and survival (Central Illustration). In-
stitutions implementing the outcome set will collect
data from hospital, clinician, and patient medical re-
cords; patient self-report; and administrative sources.
All-cause mortality was chosen, as disease-specific
mortality is more difficult to accurately capture and
is less meaningful to the individual patient.
The working group recommends collection of
baseline data and clinician-reported outcomes at the
time of the index encounter defining entry into the
set (T0). T0 would be the date of hospital discharge if
the patient’s diagnosis was the result of a hospital
admission, as this would be the point defining an
ambulatory heart failure patient. PROM and clinician-
reported measures should then be documented at
30 days (T30). These would both be repeated at
6 months following T0. In the case of an unexpected
acute event, decompensation, or hospitalization (Tn),
clinician-reported outcomes only would be
measured, with both clinician-reported outcomes and
PROM resuming at 30 days and 6 months following
Tn. Again, discharge would be the ideal measurement
point if the event led to a hospitalization. Once a
patient achieves stable follow-up, clinician-reported
outcomes and PROM would be recorded every
6 months for life. A sample timeline can be seen in
Figure 2.
Administrative and hospital data, including sur-
vival, would be collected at all time points. Given the
frequency of patient assessment, all complications,
admissions, and mortality should be attainable in a
timely fashion and limit loss to follow-up. Patient-
reported outcomes are not expected to be captured at
the time of a decompensation. Following such a
decompensation, the standard set will capture that
there has been an abrupt decline in functional ca-
pacity, an unplanned visit or readmission with dura-
tion, and subsequent modifications to treatment
(Figure 2). As the site following the ambulatory heart
failure patient will likely differ from an acute care
setting, it is unrealistic to expect a formal PROM tool
administration. PROM tools would be administered at
subsequent planned visits to ensure that a pre-
decompensation baseline has been achieved.
Biomarker measurements such as serum sodium
and natriuretic peptides were considered, but were
ultimately felt to be beyond the pragmatic nature of
the proposed outcome set. Though used in diagnosis
and monitoring treatment response, we felt these
were more appropriate as further testing prompted by
a change in the patient’s clinical condition as re-
flected in the 17-item outcome set, rather than
included in the set itself. As stated previously,
collection of such data in addition is not precluded.PROM. To meaningfully characterize patient health-
related quality of life within the functional and psy-
chosocial domains, the working group recommends
validated PROM assessment tools, standardizing
outcome assessment for self-report beyond that
captured by generic quality of life questioning. A
comprehensive 2009 review undertaken by the Uni-
versity of Oxford Department of Public Health thor-
oughly evaluated the major heart failure–specific
tools in use (12). We evaluated 3 primary PROM
assessment tools: the Kansas City Cardiomyopathy
Questionnaire (KCCQ); the Minnesota Living with
Heart Failure Questionnaire (MLHFQ); and the
Chronic Heart Failure Questionnaire (13–15). The
KCCQ and the MLHFQ are the most commonly used
PROM in heart failure, and both have been validated
and widely studied. Details regarding the validity,
reliability, and responsiveness of each tool have been
included in the Online Table S4.
Which PROM tool to recommend was controversial.
For technical quality, all 3 tools score highly in terms
of validity, reliability, and responsiveness. The
Chronic Heart Failure Questionnaire requires a
trained interviewer, which represents a substantial
barrier to implementation. Both the KCCQ and
MLHFQ address the majority of proposed domains,
and there was little to distinguish each tool based on
technical quality. To better evaluate each tool, we
used the Evaluating the Measurement of Patient-
Reported Outcomes scoring tool (16). With Evalu-
ating the Measurement of Patient-Reported
Outcomes, the KCCQ scored noticeably higher in
validity, sensitivity to change, and interpretability;
the MLFHQ scored higher in reliability and burden
(17). The KCCQ was ultimately selected given its
ability to detect and interpret score change (18). To
maximize efficiency in administration and decrease
overall collection time, the shortened KCCQ-12 was
ultimately included. This short-form tool has been
shown to preserve the favorable parameters of the
original instrument (19). Information on licensing the
KCCQ-12 is provided with the accompanying refer-
ence guide, and a sample KCCQ-12 has been included
in the Online Appendix. In addition to the KCCQ-12,
we recommend the use of the New York Heart
Association (NYHA) functional classification to
help characterize appropriate outcomes in the
“functional” domain (Central Illustration).
To supplement the KCCQ-12, the working group
recommends the use of 2 measure-specific PROM: the
Patient-Reported Outcomes Measurement Informa-
tion System Physical Function Short Form 4a and the
Patient Health Questionnaire-2 for depression and
anxiety (20,21). The tools serve to capture certain
CENTRAL ILLUSTRATION The ICHOM Standard Outcome Set for Heart Failure
Measure
Mortality
Maximum level of physical
exertion
Symptom control: shortness of breath
Symptom control: fatigue
and tiredness
Living independently/self-care
Employment
Peripheral edema
Symptom control:
disturbed sleep
Health-related quality of life
Depression and anxiety
Confidence/self-esteem
Medication side effects
Financial burden
Complications of treatment
Number of hospital
appointments
Number of hospital
readmissions
Length of stay
Supporting
Information
Not applicable
Tracked with Kansas City
Cardiomyopathy Questionnaire
and New York Heart Association
Tracked with Patient-Reported
Outcomes Measurement Information
System and Kansas City
Cardiomyopathy Questionnaire
Tracked with Kansas City
Cardiomyopathy Questionnaire
Tracked with Kansas City
Cardiomyopathy Questionnaire
Tracked with Kansas City
Cardiomyopathy Questionnaire
Yes/No
Yes/No
Due to device,
medication and/or
hospitalization
Not applicable
Not applicable
Date of admission
and discharge
Tracked with
Patient Health Questionnaire
Timing
Tracked
ongoing
Tracked
ongoing except
at acute
admissions
Tracked
ongoing except
at acute
admissions
Tracked
ongoing except
at acute
admissions
Administrative
data
Patient-and
clinician-reported
Patient-and
clinician-reported
Clinician-reported
Patient-reported
Patient-reported
Patient-reported
Administrative
data
Suggested Data
Sources
Survival
Functional
Psychosocial
Burden of care
Burns, D.J.P. et al. J Am Coll Cardiol HF. 2020;8(3):212–22.
List of outcomes included in the heart failure standard set. ICHOM ¼ International Consortium for Health Outcomes Measurement; KCCQ-12 ¼ Kansas City Cardio-
myopathy Questionnaire; N/A ¼ not applicable; NYHA ¼ New York Heart Association; PHQ-2 ¼ Patient Health Questionnaire; PROMIS ¼ Patient-Reported Outcomes
Measurement Information System; SOB ¼ shortness of breath.
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FIGURE 2 Sample Timeline for Outcome Measurement
Follow-up chronology from entry into the outcome set, including variables to be measured at each time point. PROM ¼ patient-reported outcome measure.
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219subtleties not captured by the KCCQ-12, such as
physical capability, self-care, and mental health. The
EQ-5D tool was initially proposed (22). However,
when comparing our proposed outcome set with
those outcomes covered by the above-mentioned
disease-specific PROM, the EQ-5D did not add any
additional information. Patient-Reported Outcomes
Measurement Information System is a free collection
of rigorously reviewed and tested validated outcome
measures. The Physical Function Short Form 4a
measures self-reported capability of physical activ-
ities, including dexterity, walking or mobility, central
mobility, and instrumental activities of daily living.
The Patient Health Questionnaire-2 is a validated 2-
item tool with a sensitivity of 83% and a specificity of
92% for major depression when scoring $3 (23).
Detailed information on the specific questions within
these tools can be found in the Online Appendix, and
links to each are published in the accompanying
reference guide. PROM assessment tools have been
heavily relied on, with several shortened PROM tools
being recommended. Using these tools, total data
collection time is approximately 15 min.
COMPLICATIONS. Covered under the burden of
care domain, all pharmacotherapy and device therapy
may result in treatment-related complications,significantly affecting a patient’s quality of life. It is
important to document the time and severity of each
occurrence, as well as interventions performed to
address each complication. Complications were
considered related to hospitalization, heart failure
medications, or device placement. Recommended
complications to be documented are included in the
Online Appendix.
CASE-MIX ADJUSTMENT. As robust risk adjustment
models require accounting for differences in case-mix
across regions and health care systems, the working
group defined a set of adjustment variables (Table 2).
These are factors shown to affect the course of the
heart failure patient and include both demographic
and health-related factors. To support the selection of
these factors, major heart failure registries and clinical
guidelines were searched for variables associated with
the course of the patient’s illness. The results of this
survey, with relevant citations, have been included in
the Online Appendix. Recognizing that different in-
ternational regions will have different dominant
heart failure etiologies, we have included underlying
etiology in line with current clinical practice
guidelines (6). Variable definitions, as applicable,
were identified from major health-related publica-
tions, operational definitions, or clinical practice
TABLE 2 Risk-Adjustment Variables
Measure* Supporting Information Timing Suggested Data Sources
Demographic factors
Age Date of birth At index event for HF Administrative data
Sex Sex at birth
Ethnicity Note that regulations on reporting
ethnicity may differ per country
Baseline health status
Hypertension Yes or no At index event for HF Clinician-reported
Diabetes
Renal dysfunction Serum creatinine, need for dialysis
Smoking status (current or in past year) Yes or no
Alcohol use (>1 drink a day)
Prior MI
Atrial fibrillation
Chronic lung disease Oxygen dependency
Body mass index Height and weight
Ejection fraction Determined by echocardiogram†
Underlying etiology As diagnosed
*Measure definitions can be found in the accompanying Online Appendix Section S8. †Echocardiogram is recommended, though ejection fraction can be determined by other
methods.
HF ¼ heart failure; MI ¼ myocardial infarction; N/A ¼ not applicable.
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included given inconsistent evidence and a lack of
working group consensus. Left ventricular ejection
fraction was included due to it being a common
marker of cardiac function, distinguishing heart fail-
ure with preserved or reduced ejection fraction. Steps
were also taken to align variable definitions between
the heart failure set and the related ICHOM coronary
artery disease standard set (24).
In the selection of case-mix adjustment variables,
socioeconomic variables are important factors to
consider when assessing outcomes in heart failure
patients (25). Whereas there was general agreement
that the inclusion of socioeconomic variables would
be beneficial, the working group was unable to reach
consensus regarding which specific measures to
include or which parameter(s) would be ideal. Also of
concern was how to reconcile socioeconomic vari-
ables across countries and regions, which may have
vastly different baselines and relative understandings
of higher versus lower socioeconomic status. The list
of adjustment variables was necessarily pragmatic to
allow meaningful comparisons of standardized
outcome measures across institutions, regions, and
health care systems. The list is intended to serve as a
starting point in building international risk-
adjustment models in the heart failure population.
DISCUSSION
The ICHOM heart failure working group defined a
consensus standard set of treatment, outcome, andadjustment variables to be measured within the heart
failure patient population, with a view toward care
quality and standardization. It is our hope that this
will contribute to the establishment of robust risk-
adjustment models for patient-reported outcomes
and permit comparison of the intensity, challenges,
and outcomes of heart failure care across interna-
tional boundaries. The development of the set was an
international collaboration, involving 24 members
and a project leader, across 12 countries and 6 conti-
nents. The working group included clinical leaders,
researchers, and patient representatives. To our
knowledge this is the first and largest collaboration of
its kind.
A major component of this set’s development was
surveying registry data to establish what measure-
ment efforts are currently being undertaken by health
care and research teams. The focus and structure of
existing national and international heart failure reg-
istries limit the extent to which longitudinal patient-
centered outcomes can be measured and compared.
Most registries focus on inpatient populations, short-
term mortality, and rehospitalization; patient health
status is often overlooked or not clearly defined and
standardized (9). Without this consideration, com-
plete estimates of value, as determined by outcomes
relative to the cost of care, cannot be determined (26).
In addition, recorded outcomes are not standardized
among registries. These limitations affect efforts to
understand the patient’s perspective and to compare
heart failure care processes internationally. Our goal
included focusing on what mattered most to patients
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221and is unique in that patient focus groups and in-
terviews actively informed the development of the
outcome set. In addition, we rely heavily on PROM
assessment tools to obtain validated, reproducible,
and meaningful assessments of the many domains of
health status, adding additional depth and consis-
tency beyond unstructured patient self-report.
Finally, by specifying routine follow-up intervals for
health status assessment, we hope to be able to cap-
ture multiple repeat measures and trends with
respect to long-term outcomes.
Standardizing outcome measurement allows com-
parison across regions by enabling groups to “speak
the same language” when comparing outcome mea-
sures. By specifying common measures and defini-
tions, variability and systematic error between
sample populations should be decreased. By speci-
fying exact coding practices in the accompanying
data collection reference guide, we hope to facilitate
cross-region collaboration when tracking heart failure
outcomes. Without case-mix adjustment, outcomes
between differing populations may not be directly
comparable. These additional measures allow us to
draw more meaningful conclusions when comparing
unique populations.
An important aspect of this project is the stan-
dardization of heart failure outcome measurement
across differing regions and health care systems. To
achieve this, we have published a comprehensive
data collection reference guide summarizing the set,
outcome reporting tools, adjustment variables, and
collection time points (27). This guide includes a by-
variable data collection and coding reference,
further reducing variability in outcome reporting be-
tween centers. The reference guide has been included
as a Online Appendix, and is also available from the
ICHOM website (28).
The final stage of this project is to promote
implementation of the standard set. Major hurdles
to be overcome include the following: 1) budgeting;
2) local or regional agreement of clinicians willing
to use the set; 3) ongoing evaluation and gap-
analysis of what is and is not being measured or
recorded; 4) ensuring efficient and user-friendly
means of collecting and storing clinical data; and
5) ensuring systematic and consistent collection of
PROM data. Heart failure patients may be followed
by a number of clinicians or centers, requiring
necessary communication between treating centers,
which may prove challenging. The inflection point
for feasibility may have arrived with the wider
implementation of standardized electronic health
records into which patients now routinely answerfunctional questionnaires before new and return
appointments. Though several data sources and
PROM tools are required, utilizing multiple short-
ened assessment tools has resulted in a data
collection time of only 15 min. We recognize that
implementation is not a simple task. In the short
term, we are planning pilot implementation under
leadership from working group members. Using the
results of these projects, ICHOM plans to grow in a
stepwise fashion toward broader implementation of
this set.
Pilot implementation of this outcome set is being
conducted in 13 Brazilian hospitals, coordinated by
the Brazilian National Hospital Association, including
>1,000 patients from January 2017 to present. The
main metrics for determining pilot success are follow-
up rate (>70%), absence of missing data (<10%), and
accuracy (>90%). Hospitals are free to define their
data collection instrument, ranging from spread-
sheets to integrated electronic data records. PROM
are collected by telephone contact, surveys, e-mail,
and in-person visits. The implementation experience,
in terms of process, performance, and benchmarking,
has been examined and is currently being prepared
for publication.
This outcome measurement set must be inter-
preted and implemented in the context of several
limitations. The working group was unable to reach
consensus regarding measures of socioeconomic sta-
tus, an important consideration when considering
outcomes in patients with heart failure (25). Pop-
ulations informing the development of the set tended
to be “Western” with the largest contributions from
North America and Europe. Asia was broadly repre-
sented, though the Middle East was notably absent.
No registry included a dedicated South American
population. A single registry focused on Africa.
Though standardization of outcome measurement
can facilitate cross-region comparisons, the standard
set may be biased toward Western patient pop-
ulations given the above-mentioned points.
Every effort was made to recruit an internationally
representative working group. Pragmatic consider-
ations prevented representation from every potential
region. The working group reflects the geographic
distribution of current measurement efforts. The final
composition of the group was determined by the
positive responses to our invitation. Similarly, due to
logistic constraints, patients surveyed for focus
groups were not globally representative in terms of
distribution and heart failure etiology.
With cooperation and leadership from working
group members, ICHOM has partnered with sites in
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222Europe, the Americas, and Asia to pilot and bench-
mark the implementation of the standard set. From
here we hope to build toward a more generalized
adoption of the set. Over time, we hope to be able to
identify gaps in treatment and improve quality of care
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